Carcinomas of the lung click to access explanations in the original CAP template

There is further reference to
CAP lung cancers biomarkers (2.0.1.1, Sep-2023) click to access further explanations in the original CAP template
, IASLC atlas for ALK1 and ROS1 (2e, 2016) and updated 2018 CAP-IASLC-AMP guidelines for selection of tyrosine kinase inhibitors for NSCLC patients .

specify % individual components/patterns if applicable

- Other (specify):